Docket No.: 05432/100M919-US3

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appli	cation No.: 10/644,588	Confirmation No.: 5265						
Filed:	August 20, 2003	Art Unit: 1617						
For:	THE USE OF ENANTIOMERIC PURE ESCITALOPRAM	Examiner: T. E. Betton						
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS) Commissioner for Patents								
	Box 1450							
	ndria, VA 22313-1450							
HOAd	india, 171 22313-1430							
Dear S	Sir:							
This Supplemental Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.								

A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above identified national application
B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary fee in box "i" below or paid the necessary fee in box "i" below.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:

In re Patent Application of: Connie Sanchez et al.

(Check one of the boxes A-D)

Application No.: 10/644,588 Docket No.: 05432/100M919-US3

	(check one of the boxes "i" and "ii" below:)					
	i.	Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))				
		(a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or				
		(b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.				
	ii.	Payment in the amount of the fee set forth in 1. $17(p)$, presently believed to be \$180, is enclosed.				
x D.	petition 37 Cl	(A), (B) and (C) above, but before payment of the issue fee: Applicant ons under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under FR 1.17(p) payment in the amount of \$180.00 is enclosed. Counsel tes that, upon information and belief, each item of information listed a was				
	(check	one of the boxes "a" and "b" below:)				
		x (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or				
		(b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.				

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

Application No.: 10/644,588 Docket No.: 05432/100M919-US3

A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated August 5, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(ii), a copy/copies of the U.S. Patent(s) and/or U.S. Patent Application Publication(s) on PTO/SB/08 is/are not being submitted. B. Document(s)							
< <insert &="" date="" filing="" no.="" serial="">></insert>							
Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.							
3. Cite Nos are not in the English language. In accordance with 1.98(c), Applicant states:							
An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed. The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609). A concise explanation of the relevance of document(s)							
relevance is set forth as follows: [Insert concise explanation of							
A concise explanation of the relevance of document(s) can be found on page(s) of the specification.							
A concise explanation of document(s) can be found on the attached sheet.							

Application No.: 10/644,588 Docket No.: 05432/100M919-US3

4.	No explanation of relevance is necessary for documents in English language (see reply to Comments 67 in the preamble the final rules; 1135 OG 13 at 20).									
x 5.	Other	information eration follows	being	,	for	the	examiner's			

A Canadian Office Action, dated <u>May 23, 2008</u>, which issued during the prosecution of Canadian Application No. 2,445.843.

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

Please charge our Credit Card in the amount of \$180.00 covering the fee set forth in 37 CFR 1.17(p). Credit Card Payment Form SB-2038, with a signature from an authorized cardholder, is enclosed. The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: July 16, 2008 Respectfully submitted,

By_Flynn Barrison 53,970/ Jay P. Lessler Registration No.: 41,151 DARBY & DARBY P.C. P.O. Box 770 Church Street Station New York, New York 10008-0770 (212) 527-7700 (212) 527-7701 (Fax) Attorneys/Agents For Applicant